Capital Flow Monitor · Sponsors · CIK 1808966
Verve, Inc.
9 CAMP STREET, CAMBRIDGE, MA, 02140 · 857-362-0159
Other Technology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$16.4M
Sold
$12.8M
% sold
77.7%
Investors
36
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | D ·current | 506(b) | $16.4M | $12.8M | 77.7% | 36 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Ignacio Galiana Bujanda — Executive Officer / Director, Cambridge, MA
- Conor James Walsh — Director, Cambridge, MA
- Micah Rosenbloom — Director, Cambridge, MA
-
Dayna Grayson — Director, Cambridge, MA
4 other raises
- Construct Capital Select Fund II, L.P. $150.0M of $150.0M · 100.0%
- US Chemical Technologies, Inc. $30.0M of $30.0M · 100.0%
- Copia Automation, Inc. $18.0M of $23.1M · 77.9%
- Hadrian Automation, Inc. $131.3M of $151.3M · 86.8%
- Andrew Payne — Director, Cambridge, MA
-
Arunas Chesonis — Director, Cambridge, MA
2 other raises
- OrganiCore Nuclear, Inc. $15.0M of $65.0M · 23.1%
- Safar Partners Fund III, L.P. $229.4M of $300.0M · 76.5%
-
John McEleney — Director, Cambridge, MA
3 other raises
- Prometheus Therapeutics Inc. $2.7M of $6.5M · 42.2%
- NeuroFine Corp. $1.0M of $1.0M · 100.0%
- Deinde Medical Corp. $185K of $2.0M · 9.3%
- Steve Van Ermen — Director, Cambridge, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.